{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:41:25Z","timestamp":1793155285561,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2020YFA0112700"],"award-info":[{"award-number":["2020YFA0112700"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ajoc.2022.101370","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:03:38Z","timestamp":1643483018000},"page":"101370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma\u2014\u2014a case report of a Chinese patient"],"prefix":"10.1016","volume":"25","author":[{"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-936X","authenticated-orcid":false,"given":"Chaoyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghuai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-1762","authenticated-orcid":false,"given":"Guohong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajoc.2022.101370_bib1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101370_bib2","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ajoc.2022.101370_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ajoc.2022.101370_bib4","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.clim.2019.108317","article-title":"Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy","volume":"210","author":"Adamus","year":"2020","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101370_bib5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000000119","article-title":"Autoimmune retinopathy and antiretinal antibodies: a review","volume":"34","author":"Grewal","year":"2014","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101370_bib6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.survophthal.2012.09.001","article-title":"Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management","volume":"58","author":"Rahimy","year":"2013","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101370_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.autrev.2009.01.002","article-title":"Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy","volume":"8","author":"Adamus","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101370_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/00006982-200512000-00020","article-title":"Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review","volume":"25","author":"Chang","year":"2005","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101370_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3341\/kjo.2007.21.4.261","article-title":"Cancer-associated nummular loss of the retinal pigment epithelium","volume":"21","author":"Lee","year":"2007","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101370_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ajoc.2016.12.024","article-title":"Improvements of visual function and outer retinal morphology following spontaneous regression of cancer in anti-recoverin cancer-associated retinopathy","volume":"5","author":"Suimon","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101370_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","article-title":"Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone","volume":"68","author":"Keime-Guibert","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ajoc.2022.101370_bib12","first-page":"115","article-title":"Autoimmune retinopathy: current concepts and practices (an American ophthalmological society thesis)","author":"Sen","year":"2018","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:59:29Z","timestamp":1762527569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":12,"alternative-id":["S2451993622001165"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101370","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma\u2014\u2014a case report of a Chinese patient","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101370"}}